Free Newsletter
Merck shareholders bless deal for Schering
Free newsletter via e-mail
Tools
It's official: Merck got shareholder approval for its $41 billion merger with Schering-Plough, with preliminary vote results showing that more than 99 percent of the stockholders gave a thumbs-up to the deal. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: